Illumina Appoints Marc Stapley as SVP and CFO
Illumina, a developer, manufacturer and marketer of life science tools, has named Marc Stapley, former senior vice president (SVP), finance, at Pfizer and Americas chief financial officer (CFO) at Alcatel-Lucent, as senior vice president and CFO. He will report to president and chief executive officer (CEO) Jay Flatley and will oversee Illumina’s finance, accounting, facilities and investor relations functions. Stapley will also become part of Illumina’s executive management team, which is responsible for directing all aspects of company strategy, planning and operations.
Stapley is expected to join Illumina on 20 January 2012. At that time he will assume the CFO responsibilities currently held by Christian Henry. Henry, who for the past two years has been serving in both the CFO role and as general manager of the company’s genetic analysis business (formerly life sciences), will now be able to fully dedicate his time to leading the genetic analysis business.
Stapley joins Illumina from Pfizer where he served as SVP responsible for global financial processes and systems, leading integration efforts in both the Wyeth and King Pharmaceutical acquisitions and providing oversight to the company’s largest technology investment programme. Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas CFO. He also worked as finance director and controller for several groups at Cadence Design Systems.
Stapley began his career as an Auditor at Coopers & Lybrand. He holds a first class BSc (Honors) in Mathematics from the University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.